Q2 2026 saw 10% revenue growth and 12% adjusted EBITDA growth, driven by strong Specialty and Affordable Medicines performance and robust new product launches. Full-year 2026 guidance was raised across all key metrics, and the Kashiv acquisition is on track to expand biosimilar leadership.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.